Why the study?
Does levosimendan improve clinical and hemodynamic outcomes compared to dobutamine in acute heart failure patients on beta-blockade treatment?
Does levosimendan improve clinical and hemodynamic outcomes compared to dobutamine in acute heart failure patients on beta-blockade treatment?
No takes yet. Share an insight, caveat, or question.
In acute heart failure patients on beta-blockers, levosimendan is not superior to dobutamine and is associated with a high rate of hypotension, questioning its routine use given its high cost.
Ömerovic et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: